The following transcript has been edited for clarity.

Hi, I’m Arshad M. Khanani, MD, FASRS, at ASRS 2026 in Montreal. I saw the results of the long-term data from RGX-314 (Regenxbio/AbbVie) presented here in the late-breaker section. I am happy and honored to be a coauthor on that abstract.

I’m really excited about the potential of RGX-314, or sura-vec (surabgene lomparvovec), in reducing treatment burden for our patients with wet age-related macular degeneration (nAMD). Gene therapy delivered subretinally as a drug delivery platform is an important advancement for our field. I’m looking forward to the phase 3 data from ATMOSPHERE and ASCENT from the sura-vec program, which is going to come out later this year.

Gene therapy really can be a paradigm shift for our patients, because we know that the real-world treatment outcomes are much inferior to clinical trials because of the treatment burden. If we can have a large subset of patients not needing any more injections after 1 subretinal gene therapy injection or reduce the treatment burden for patients who get chronic injections by delivering gene therapy, I think it’s going to be well accepted by the patients as well as physicians.

I’m looking forward to the phase 3 data. This will be the first pivotal gene therapy program designed for nAMD, and I hope that potentially it is positive and we can implement gene therapy in our clinical practice in the next few years so we can optimize long-term outcomes for our patients with wet AMD. RP